Urbanska, Marta http://orcid.org/0000-0002-6517-5958
Muñoz, Hector E. http://orcid.org/0000-0001-7851-2549
Shaw Bagnall, Josephine http://orcid.org/0000-0003-3415-3614
Otto, Oliver http://orcid.org/0000-0003-0280-5374
Manalis, Scott R. http://orcid.org/0000-0001-5223-9433
Di Carlo, Dino http://orcid.org/0000-0003-3942-4284
Guck, Jochen http://orcid.org/0000-0002-1453-6119
Funding for this research was provided by:
Alexander von Humboldt-Stiftung (Alexander von Humboldt Professorship to J.G.)
Bundesministerium für Bildung und Forschung (03Z22CN11)
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (U54 CA217377)
Ludwig Center for Molecular Oncology
United States Department of Defense | United States Navy | Office of Naval Research (N00014-16-1-2997)
Article History
Received: 7 April 2019
Accepted: 23 March 2020
First Online: 27 April 2020
Competing interests
: M.U., H.E.M., J.S.B. and J.G. declare no competing interests. O.O. is a shareholder of Zellmechanik Dresden GmbH distributing real-time deformability cytometry; Zellmechanik Dresden GmbH owns a patent for Real-Time Deformability Cytometry (RT-DC): EU patent under the number EP 30 036 520 B1. S.R.M. is a founder of Travera and Affinity Biosensors. D.D. has financial interests in Cytovale Inc., which is commercializing deformability cytometry technology.